Early microvascular obstruction, assessed by CMR, was associated with a 66.2% occurrence of the primary composite endpoint compared to 42.4% in patients without MVO, with HR 2.20 indicating a significantly higher risk of adverse outcomes.
Cohort (n=129)
No
Does the presence of early microvascular obstruction assessed by CMR predict adverse clinical outcomes in patients reperfused by pPCI for STEMI?
Early microvascular obstruction assessed by first-pass CMR is a strong independent predictor of long-term cardiovascular morbidity at 5 years in patients after STEMI.
Effect estimate: HR 2.20 (95% CI 1.11-4.36)
Absolute Event Rate: 66.2% vs 42.4%
p-value: p=0.024
Early MVO, as assessed by first-pass CMR, is an independent long-term prognosticator for morbidity after AMI.
Klug et al. (Sun,) conducted a cohort in acute ST-elevation myocardial infarction (n=129). early microvascular obstruction (MVO) assessment by CMR vs. patients without early MVO was evaluated on composite of death, myocardial re-infarction, stroke, repeat revascularization, recurrence of ischemic symptoms, atrial fibrillation, congestive heart failure and hospitalization (HR 2.20, 95% CI 1.11-4.36, p=0.024). Early microvascular obstruction, assessed by CMR, was associated with a 66.2% occurrence of the primary composite endpoint compared to 42.4% in patients without MVO, with HR 2.20 indicating a significantly higher risk of adverse outcomes.